nVerses Capital’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
nVerses Capital's BBIO Position: Q3 2026 in Review
nVerses Capital sold out of BridgeBio Pharma (BBIO) in Q3 2026, closing a stake of 2,753 shares — an estimated $205K sold.
nVerses Capital first reported a position in BBIO in Q2 2026 and held it in 1 quarter. The position peaked at $205K in Q2 2026. 469 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- nVerses Capital reported no remaining BridgeBio Pharma position as of Q3 2026 after selling out during the quarter.
- nVerses Capital sold 2,753 BridgeBio Pharma shares in Q3 2026, an estimated $205K.
- nVerses Capital first reported a position in BridgeBio Pharma in Q2 2026 and held it in 1 quarter.
- nVerses Capital's BridgeBio Pharma position peaked at $205K in Q2 2026.
- 469 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on nVerses Capital's 13F filing for Q3 2026.